<DOC>
	<DOCNO>NCT02669147</DOCNO>
	<brief_summary>This prospective observational study evaluate effectiveness safety Enzalutamide Castration Resistant Prostate Cancer ( CRPC ) patient decide administer Enzalutamide anti-androgen therapy . CRPC Patients observe PSA disease progression anti-androgen therapy decide administrate Enzalutamide dose Enzalutamide 160 mg orally daily observed practical treatment . Total research term 4 year , consist 2-year case registration term 2-year observational term .</brief_summary>
	<brief_title>A Study Determine Enzalutamide Long-term Safety Efficacy After Anti-androgen Therapy CRPC</brief_title>
	<detailed_description />
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm prostate cancer . 2 . Patients receive receive continuous androgen deprivation therapy use gonadotropinreleasing hormone ( GnRH ) agonist antagonist ( medical castration ) , testicles removal surgery ( surgical castration ) . 3 . Castration resistant prostate cancer ( CRPC ) patient observed disease progression castration treatment imply treatment resistant . 4 . CRPC patient conduct antiandrogen alternate therapy show 1 ) observe one disease progression show 2 ) therapy decide administer enzalutamide . Note 1 ) antiandrogen alternate therapy define therapy flutamide administration bicalutamide . Note 2 ) Disease progression criterion antiandrogen alternate therapy ① PSA progression antiandrogen alternate therapy : PSA increase 25 % compare low test result initial dose antiandrogen alternate therapy ( flutamide ) increase 2ng/ml . ②Confirmed disease progression soft tissue lesion define RECIST v1.1 . ③Confirmed disease progression bone lesion define 2 new appearance bone lesion bone scintigraphy . 5 . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 02 6 . Patients sign write informed consent participate study 1 . Patients administer administration history enzalutamide , abiraterone , docetaxel cabazitaxel 2 . Patients history seizure predispose disease seizure 3 . Patients severe liver dysfunction 4 . Patients previous history hypersensitivity component drug administer study 5 . Patients consider inappropriate study participation investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>